In a significant development for the treatment of drug-resistant tuberculosis (TB), Johnson & Johnson has announced that SIRTURO (bedaquiline) has received full approval from the U.S. Food and Drug Administration (FDA) and the European Commission (EC). This approval marks a pivotal milestone in the fight against pulmonary TB that is resistant to standard treatments like […]
Tuberculosis (TB) remains one of the most persistent and deadly infectious diseases globally. Caused by various strains of the Mycobacterium tuberculosis bacteria, TB primarily targets the lungs but can also affect other parts of the body, such as the bones, glands, and intestines. Despite advancements in modern medicine, the emergence of antibiotic-resistant strains has posed […]
